Indication: Lymphoma
A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with
Rituximab Versus Immunochemotherapy in Patients with Relapsed or
Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)
Sub-indication: Hematological Malignancies
Study Type: Drug Study
Principal Investigator: Joseph Maly, M.D.Norton Cancer Institute
Sponsor: Sponsor: ADC Therapeutics SA
